期刊文献+

逆转大鼠胶质瘤细胞耐药性MRP1-siRNA的筛选实验 被引量:1

Screening the multidrug resistant-associated protein 1-small interference RNA that may reverse the resistance of rat multidrug resistant glioma cell line C6 cells
暂未订购
导出
摘要 目的 拟筛选出能逆转大鼠胶质瘤多药耐药细胞株C6/VP16对依托泊苷耐药性的多药耐药相关蛋白1基因小干扰RNA(MRP1-siRNA)。方法 人工合成4对靶向MRP1的siRNA分别为siRNA1、siRNA2、siRNA3和siRNA4,以脂质体2000作为载体;以6-羧基荧光素标记转染siRNA的C6细胞评价转染效率;采用逆转录-PCR和免疫印迹分别检测MRP1mRNA和蛋白的表达。细胞计数盒-8试剂盒检测转染前后依托泊苷对肿瘤细胞的半生长抑制浓度(IC50)。结果 与siRNA1、siRNA4相比,siRNA2、siRNA3对MRP1基因的抑制作用更明显。转染siRNA2前后,依托泊苷对C6细胞的半生长抑制浓度分别为(0.873±0.0462)、(0.0927±0.039)μg/μl,两者相较差异显著(P<0.05)。结论 siRNA2、siRNA3可以有效抑制MRP1基因的表达,并能逆转肿瘤细胞对依托泊苷的耐药性。 Objective To screen a Muhidrug resistant-associated protein 1-small interference RNA (MRPI-siRNA) that may effectively reverse the etoposide (VP16) resistance of rat multidrug resistant glioma cell line C6 cells (C6/VP16). Methods Four strands of siRNA targeting MRP1 were designed and synthesized. Lipofectamine 2 000 was used as a vector to transfect siRNA into rat glioma multidrug-resistant cell line C6 cells. The expressions of MRP1 mRNA and protein were determined respectively by reverse transcription-polymerase chain reaction and western blot. Cell counting kit-8 was applied to examination of the number of the glioma cells and the half maximal inhibitory concentration (IC50) value of vp16 to the cell line before and after the transfection. Results The inhibitory effects of siRNA2 and siRNA3 on the target (MMP1) gene were significantly stronger than those of siRNA1 and siRNA4 (P〈0.05). IC50 of VP16 to C6 cells [(0.0927±0.039)ug/ul] was significantly lower after the siRNA2 transfection than that [(0.873±0.0462) ug/ul] before the siRNA2 transfection (P〈0.05). Conclusion siRNA2 and siRNA3 can effectively inhibit MRP1 gene expression, and significantly reverse the resistance of C6 cells to VP16.
出处 《中国临床神经外科杂志》 2013年第3期154-157,共4页 Chinese Journal of Clinical Neurosurgery
关键词 胶质瘤 C6细胞 多药耐药相关蛋白1 依托泊苷 小干扰RNA Glioma C6 cells Muhidrug resistance associate protein-i Etoposide Small interfering RNA
  • 相关文献

参考文献11

  • 1Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response [J]. Pharmacology, 2008. 81(4): 275-300.
  • 2Baguley BC. Multiple drug resistance mechanisms in cancer [J]. Mol Bioteehnol, 2010, 46(3): 308-316.
  • 3de Faria GP, de Oliveira JA, de Oliveira JG, et al. Differences in the expression pattern of P-glyeoprotein and MRP1 in low-grade and high-grade gliomas [J]. Cancer Invest, 2008, 26(9): 883-889.
  • 4李乾锋,徐海涛,王龙,黄书岚.神经胶质瘤C6/VP16多药耐药细胞株的建立[J].中国临床神经外科杂志,2012,17(7):414-416. 被引量:4
  • 5Loe DW, Deeley RG, Cole SP. Biology of the multidrug re- sistance-associated protein MRP [J]. Eur J Cancer, 1996, 32A(6): 945-957.
  • 6O'Connor R, 0"Leary M, Ballot J, etal. A phase I clinicaland pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer [J]. Cancer Chemother Pharmacol, 2007. 59(1): 79-87.
  • 7Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs [J]. Genes Dev, 2001, 15(2): 188-200.
  • 8Shabalina SA, Spiridanov AN, Ogartsov AY. Computational models with thermodynamic and composition features im- prove siRNA design [J]. BMC Bioinformatics, 2006, 7: 65.
  • 9Holen T, Amarzgnioui M, Wiiger MT, et al. Positional ef- fects of short interfering RNAs targeting the human coagu- lation trigger tissue factor [J]. Nucleic Acids Res, 2002, 30 (8): 1757-1766.
  • 10KKars MD, Ieri OD, Gtlndtlz U. Drug resistant breast can- cer cells overexpress ETS1 gene [J]. Biomcd Pharmacother, 2010, 64(7): 458--462.

二级参考文献14

  • 1Walter KA, Tamargo RJ, Olivi A, et al . Intratumoral chemotherapy [J]. Neurosurgery, 1995, 37:1128~1145.
  • 2Tamargo R J, Epstein JI, Reinhard CS, et al. Brain biocompatibility of a biodegradable, controlled-release polymer in rats [J]. J Biomed Mater Res, 1989, 23: 253~266.
  • 3Hochberg F, Pruitt A. Assumptions in the radiotherapy of glioblastoma [J]. Neurology 1980, 30: 907~911.
  • 4Singh DK, Ray AR. Biomedical applications of chitin, chitosan and their derivatives [J]. JMS Rev Macromol Chem Phys. 2000, 40(1): 71~77.
  • 5Lamer KJB, Van Engelen BGM, Gabreela FJM, et al . Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorder [J]. Acta Neurol Scand,1995, 92: 147~151.
  • 6Yang LY, Trujillo JM . Biological characterization of multi- drug resistant human colon carcinoma sublines induced/ selected by two methods[J]. Cancer Res, 1990, 50(6): 3218- 3225.
  • 7Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, ceL- lular, and pharmacological aspects of the multidrug trans- porter [J]. Annu Rev Pharmacol Toxicol, 1999, 39(8): 361- 398.
  • 8Krishna R, Mayer LD. Multidrug resistance (MDR) in can- cer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J]. Eur J Pharm Sci, 2000, 11(4): 265- 283.
  • 9Ling V. Muhidrug resistance: molecular mechanisms and clinical relevance. [J]. Cancer Chemother Pharmcol, 1997, 40 (Suppl): S3-8.
  • 10Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance associated protein MRP [J]. Eur J Cancer, 1996, 32A(6): 945-957.

共引文献6

同被引文献2

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部